209 related articles for article (PubMed ID: 17332973)
1. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha.
Hanta I; Ozbek S; Kuleci S; Sert M; Kocabas A
Clin Rheumatol; 2007 Nov; 26(11):1867-70. PubMed ID: 17332973
[TBL] [Abstract][Full Text] [Related]
2. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.
Jahng AW; Tran T; Bui L; Joyner JL
Transplantation; 2007 Jun; 83(12):1557-62. PubMed ID: 17589337
[TBL] [Abstract][Full Text] [Related]
3. Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients.
Nobre CA; Callado MR; Lima JR; Gomes KW; Martiniano GV; Vieira WP
Rheumatol Int; 2012 Sep; 32(9):2769-75. PubMed ID: 21822912
[TBL] [Abstract][Full Text] [Related]
4. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic.
Mor A; Bingham CO; Kishimoto M; Izmirly PM; Greenberg JD; Reddy S; Rosenthal PB
Ann Rheum Dis; 2008 Apr; 67(4):462-5. PubMed ID: 17711866
[TBL] [Abstract][Full Text] [Related]
6. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients.
Hanta I; Ozbek S; Kuleci S; Kocabas A
Clin Rheumatol; 2008 Sep; 27(9):1083-6. PubMed ID: 18320137
[TBL] [Abstract][Full Text] [Related]
8. [Recommendations for the prevention and management of tuberculosis in patients treated with tumor necrosis factor alpha inhibitors: a consensus of lithuanian pulmonologists and rheumatologists].
Malakauskas K; Zablockis R; Venalis A; Butrimienė I; Baranauskaitė A; Nargėla RV; Sakalauskas R
Medicina (Kaunas); 2011; 47(3):187-91. PubMed ID: 21822042
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy.
Sung YK; Cho SK; Kim D; Won S; Choi CB; Kim TH; Jun JB; Yoo DH; Bae SC
Korean J Intern Med; 2018 Sep; 33(5):1016-1024. PubMed ID: 28288508
[TBL] [Abstract][Full Text] [Related]
10. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
Sichletidis L; Settas L; Spyratos D; Chloros D; Patakas D
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1127-32. PubMed ID: 17044206
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis.
Hazlewood GS; Naimark D; Gardam M; Bykerk V; Bombardier C
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1722-31. PubMed ID: 23836530
[TBL] [Abstract][Full Text] [Related]
13. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
Fountain FF; Tolley E; Chrisman CR; Self TH
Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Fresard I; Bridevaux PO; Rochat T; Janssens JP
Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
[TBL] [Abstract][Full Text] [Related]
15. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
16. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.
Sotsuka T; Sasaki Y; Hirai S; Yamagishi F; Ueno K
In Vivo; 2011; 25(5):803-12. PubMed ID: 21753138
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.
Hsia EC; Cush JJ; Matteson EL; Beutler A; Doyle MK; Hsu B; Xu S; Rahman MU
Arthritis Care Res (Hoboken); 2013 Feb; 65(2):309-13. PubMed ID: 22782640
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area.
Moon HH; Park SY; Kim JM; Park JB; Kwon CHD; Peck KR; Kim SJ; Lee SK; Joh JW
Ann Transplant; 2017 Jun; 22():338-345. PubMed ID: 28579606
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay.
Dinser R; Fousse M; Sester U; Albrecht K; Singh M; Köhler H; Müller-Ladner U; Sester M
Rheumatology (Oxford); 2008 Feb; 47(2):212-8. PubMed ID: 18208824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
